C4 Therapeutics, Inc. (CCCC)

C4 Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	-132.49	-128.18	-83.89	-66.34	-42.57
Depreciation & Amortization	8.04	7.57	2.91	2.84	2.74
Share-Based Compensation	27.24	30.02	21.51	3.43	1.64
Other Operating Activities	-9.62	-15.35	-27.49	-7.19	85.33
Operating Cash Flow	-106.84	-105.94	-86.97	-67.25	55.61
Capital Expenditures	-1.71	-5.5	-1.28	-0.65	-1.29
Change in Investments	160.06	63.92	-188.06	-189.86	-0.33
Investing Cash Flow	158.35	58.42	-189.34	-190.51	-1.62
Share Issuance / Repurchase	57.62	0.78	171.51	192.16	0.24
Debt Issued / Paid	-12.5	0	0	11.97	0
Other Financing Activities	0.37	0.37	-0.11	144.8	-
Financing Cash Flow	45.49	1.15	171.4	348.93	0.24
Net Cash Flow	97	-46.37	-104.9	91.18	54.24
Free Cash Flow	-108.55	-111.44	-88.24	-67.9	54.33
Free Cash Flow Margin	-522.96%	-358.36%	-192.73%	-204.55%	254.09%
Free Cash Flow Per Share	-2.19	-2.28	-1.92	-5.97	39.60

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).